Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms–Single-center Experience

Varování

Publikace nespadá pod Fakultu sportovních studií, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	KISSOVÁ Jarmila OVESNÁ Petra PENKA Miroslav BULIKOVÁ Alena KISS Igor
Rok publikování	2014
Druh	Článek v odborném periodiku
Časopis / Zdroj	ANTICANCER RESEARCH
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Obor	Onkologie a hematologie
Klíčová slova	Second malignancies; hydroxyurea; myeloproliferative neoplasm; skin cancer
Popis	The aim of this work was to retrospectively analyze patients with Philadelphia-negative myeloproliferative neoplasms through evaluation of frequency and characteristics of second malignancies (other than acute leukaemia and myelodysplastic syndrome). Patients and Methods: Records of 172 patients were reviewed; an analysis was performed on data from 66 patients treated with hydroxyurea, 105 patients treated with other cytoreductive therapy, and 25 patients without treatment. Results: A higher occurrence of second malignancies was found in the group treated with hydroxyurea (7.6%; other cytoreduction: 1.2%; without therapy: 0). After a median follow-up of 89 months in the hydroxyurea group, 13 patients developed second cancer during hydroxyurea therapy, located on the skin (68.75%) and other sites (31.25%). Conclusion: The incidence of second malignancies during hydroxyurea therapy in our cohort patient was significantly higher than the incidence of malignancies in the Czech population of corresponding age.